DOCUSIGN, INC.

DOCU

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 8,480Value: $586K

**Signal Note: DOCU Position Initiation** Eventide's entry into DocuSign appears disconnected from biotech fundamentals—DOCU is a SaaS/contract management platform with no direct drug development exposure. This likely reflects portfolio rebalancing or conviction in DOCU's operational efficiency thesis rather than a biotech-specific catalyst, warranting clarification on whether this signals a broadening of Eventide's values-based mandate beyond traditional life sciences.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: